workshop program

This course is designed for personnel in the pharmaceutical and biotechnology industries and contract research organisations who want to understand the rationale, methodology and importance of in vitro ADME and DMPK studies during the drug discovery and development processes. This course is focused at individuals within industry wanting to expand their knowledge of in vitro ADME and DMPK for example, medicinal chemists wishing to understand the importance of early ADME testing or project managers wanting to understand the DMPK profile of lead compounds.

The various types of in vitro ADME and DMPK studies will be discussed detailing the benefits of performing these assays early in drug discovery, an overview of the methodologies currently available and how these data can be used to make informed decisions based upon a compounds overall ADME/DMPK profile.

1.00 – 1.10	Introduction and overview
1.10 – 2.00	Membrane permeability and drug transporters
2.00 – 3.00	In vitro drug metabolism
3.00 - 3.15	Coffee Break
3.15 - 4.15	CYP450 mediated drug-drug interactions
4.15 - 5.00	Application of in vitro data in drug development

8.00	Registration & Breakfast
9.00	Welcome by Anthony Baxter (CEO, Cyprotex)
Part I. Optimising DMPK: Approaches
9.15	Edward Kerns (Consultant, Discovery ADME) Integrating in vitro and in vivo DMPK studies to guide structure optimization in drug discovery
10.00	Rod Cole (Associate Director, Drug Metabolism and Pharmacokinetics, Abbott Bioresearch Center) Bioanalytical technologies for early DMPK discovery support: Practical considerations and applications
10.45	Coffee Break
11.15	Bernard Murray (Senior Research Scientist I, Gilead) Targeted solutions to DMPK problems: Avoiding unnecessary screening
12.00	Norman Huebert (Team Leader & Research Fellow ADME, Johnson & Johnson) Research strategies in LG and LO: Combining in vitro and in vivo ADME approaches
12.45	Lunch
Part II: Optimising the notorious blood-brain barrier penetration
13.45	Peng Hsiao (Research Assistant, Jashvant D Unadkat Lab, University of Washington) P-gp based drug interactions at the blood- brain barrier: Fact or fantasy?
14.30	Simon Thomas (Head of Scientific Computing, Cyprotex) Physiologically based pharmacokinetic/pharmacodynamic modelling for lead optimisation of CNS-Active therapeutics
15.15	Coffee Break
Part III. Programs de-risking: Reducing late attrition and toxicity risks via new approaches
15.45	Konstantine Skordos (Section Manager, DMPK, GSK) Reducing late stage attrition: Predicting hepatotoxicity in the clinic from early preclinical screening data
16:30	Katya Tsaioun (Chief Scientific Officer, Cyprotex) New technologies for mechanistic toxicology in lead de-risking: CellCiphr™ Cellular Systems Biology (CSB™) approach
17.15	Conclusion by Anthony Baxter (CEO, Cyprotex)
17.30	Networking & Drinks Reception